Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: The Pharmaceutical Research and Manufacturers of America (PhRMA) supports the FDA and ICH's efforts to revise the M4Q(R2) guidance to enhance clarity, reduce duplication, and support global harmonization of pharmaceutical submissions. They provide specific recommendations to improve the structure of the Common Technical Document (CTD), particularly regarding Core Quality Information (CQI), lifecycle management, and the integration of medical device information.